Carter Bankshares, Inc. is a Martinsville, Virginia-based bank holding company and the parent of Carter Bank. The company has spent 2026 repositioning its balance sheet after a series of notable transactions, including the sale of its Bearing Insurance Group membership interest in May and the resolution of a large nonperforming credit relationship earlier in the year. Those moves generated roughly $100.9 million in aggregate nonrecurring gains during the first half of 2026, which inflated reported results. Because those gains will not repeat, the third quarter offers investors a cleaner read on the bank's underlying earnings power, its ability to grow loans, and whether its improving net interest margin can sustain profitability without one-off tailwinds.
Analysts expect CARE to report third-quarter 2026 earnings of about $0.53 per share, with consensus revenue near $47 million. That compares with EPS of $0.26 in the third quarter of 2025, highlighting how much headline profitability has expanded even after adjusting for the company's unusual transactions. For context, second-quarter 2026 net income was $28.9 million, or $1.31 diluted EPS, but that figure included a $35.9 million pre-tax gain from the insurance sale; adjusted net income was $11.6 million. First-quarter 2026 net income of $85.8 million, or $3.88 per share, was similarly boosted by credit-loss recoveries tied to a loan sale.
Given this backdrop, the $0.53 consensus estimate is best understood as a return to more normalized, core operating earnings. Investors will also watch net interest income, which reached $40.0 million in the second quarter, up from $32.4 million a year earlier, along with net interest margin trends and loan growth. The company previously reported annualized loan growth of 6.1% net of its loan sale transaction, driven by commercial and small business lending. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Sentiment heading into the third-quarter report is cautiously optimistic but focused on sustainability. The stock has had a volatile history around earnings: it rose about 2.98% following the July 2026 release, fell roughly 2.09% after the April 2026 report, and dropped about 6.34% after the October 2025 release. Because recent quarters were dominated by transaction-related gains, the key risk is that investors read through to core operating results and react to the quality of loan growth, margin expansion, and expense discipline rather than headline EPS. A cleaner quarter could reinforce confidence, while any sign of softening credit trends or slower loan demand could pressure shares.
Following the report, investors should monitor several factors that will shape Carter Bankshares' trajectory into 2027. Net interest margin will be central. Management has described the balance sheet as slightly liability sensitive, meaning the bank could benefit if the Federal Reserve lowers interest rates, particularly given the short-term nature of its certificates of deposit (CD) portfolio.
Loan growth is another important signal. The company has pointed to a healthy commercial and small business pipeline, along with construction lending commitments expected to fund over the next 12 to 18 months. Whether that pipeline converts into sustained, profitable loan balances will matter more than the nonrecurring gains that dominated the first half of 2026.
Credit quality should also remain in focus. The resolution of a large nonperforming credit relationship dramatically improved metrics, with nonperforming assets falling to $27.4 million at March 31, 2026, from $244.1 million at the end of 2025. Investors will want confirmation that underlying credit trends remain stable. Finally, the divestiture of the insurance business removes a revenue stream, so watching how core noninterest income and expense management evolve will help clarify the bank's normalized earnings run-rate.
I often rely on Tickeron’s AI Screener when preparing for earnings like this one. It lets me quickly filter regional banks by technical patterns, fundamentals, and momentum signals, giving me a clearer picture of how CARE stacks up against peers without spending hours on manual analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CARE moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend. In 15 of 24 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 62%.
The Momentum Indicator moved below the 0 level on November 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CARE as a result. In 45 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.
The Moving Average Convergence Divergence Histogram (MACD) for CARE turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 22 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CARE's RSI Indicator exited the oversold zone, 20 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 58 cases where CARE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where CARE advanced for three days, in 209 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
CARE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Profit vs. Risk Rating rating for this company is 20 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.233) is normal, around the industry mean (1.265). P/E Ratio (4.947) is within average values for comparable stocks, (13.523). Projected Growth (PEG Ratio) (0.130) is also within normal values, averaging (1.194). Dividend Yield (0.014) settles around the average of (0.036) among similar stocks. P/S Ratio (3.140) is also within normal values, averaging (3.751).
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. CARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a state commercial bank
Industry RegionalBanks